Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 70

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

Tal, Perry, Eizenberger, Shay, Cohen, Elad, Goldfinger, Naomi, Pietrokovski, Shmuel, Oren, Moshe, Rotter, Varda·2016·Oncotarget
DOI 10.18632/oncotarget.7857
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7857

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
  2. Lu, 2002, Live or let die: the cell's response to p53, Nat Rev Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
  3. Fersht, 2008, Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA, Nucleic Acids Res, 36, 1589, 10.1093/nar/gkm1040 · DOI
  4. Levine, 2000, Surfing the p53 network, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
  5. Wiman, 2007, Shaping genetic alterations in human cancer: the p53 mutation paradigm, Cancer Cell, 12, 303, 10.1016/j.ccr.2007.10.001 · DOI · Paper page
  6. Pfeifer, 2001, TP53 mutation spectrum in lung cancers and mutagenic signature of components of tobacco smoke: lessons from the IARC TP53 mutation database, Mutagenesis, 16, 551, 10.1093/mutage/16.6.551 · DOI
  7. Oren, 2003, Decision making by p53: life, death and cancer, Cell Death Differ, 10, 431, 10.1038/sj.cdd.4401183 · DOI · Paper page
  8. Fersht, 2004, Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations, J Biol Chem, 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
  9. Fersht, 2005, Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations, J Biol Chem, 280, 16030, 10.1074/jbc.M500179200 · DOI · Paper page
  10. Prives, 1996, Regulation of mutant p53 temperature-sensitive DNA binding, J Biol Chem, 271, 25468, 10.1074/jbc.271.41.25468 · DOI
  11. Lane, 2000, An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo, Oncogene, 19, 2312, 10.1038/sj.onc.1203593 · DOI · Paper page
  12. Evan, 2005, Temporal dissection of p53 function in vitro and in vivo, Nat Genet, 37, 718, 10.1038/ng1572 · DOI · Paper page
  13. El-Deiry, 2003, Restoring p53-dependent tumor suppression, Cancer Biol Ther, 2, S55
  14. Lim, 2007, Mechanism of DNA-binding loss upon single-point mutation in p53, J Biosci, 32, 827, 10.1007/s12038-007-0083-3 · DOI
  15. Fersht, 2000, Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
  16. Winter, 2001, The ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins, Oncogene, 20, 2318, 10.1038/sj.onc.1204316 · DOI
  17. Lane, 1995, Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein, Oncogene, 10, 389
  18. Mandecki, 1998, Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library, Oncogene, 16, 1993, 10.1038/sj.onc.1201717 · doi:10.1038/sj.onc.1201717
  19. Kandil, 1993, Wild-type p53 adopts a ‘mutant’-like conformation when bound to DNA, The EMBO journal, 12, 1021, 10.1002/j.1460-2075.1993.tb05743.x · DOI · Paper page
  20. Kandil, 1993, Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants, The EMBO journal, 12, 5057, 10.1002/j.1460-2075.1993.tb06199.x · DOI · Paper page
  21. Geiger, 2014, Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation, Proceedings of the National Academy of Sciences of the United States of America, 111, 7006, 10.1073/pnas.1320428111 · DOI
  22. Oren, 2015, Down-regulation of LATS kinases alters p53 to promote cell migration, Genes & Development, 29, 2325, 10.1101/gad.268185.115 · DOI
  23. Deisseroth, 1994, A temperature-sensitive mutant of human p53, The EMBO journal, 13, 2535, 10.1002/j.1460-2075.1994.tb06543.x · DOI
  24. Vousden, 1996, Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function, Molecular and Cellular Biology, 16, 4952, 10.1128/MCB.16.9.4952 · DOI · Paper page
  25. Thornton, 2002, Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein, Hum Mutat, 19, 149, 10.1002/humu.10032 · DOI
  26. Sun, 2010, Targeting p53 for Novel Anticancer Therapy, Translational Oncology, 3, 1, 10.1593/tlo.09250 · DOI
  27. Selivanova, 2015, Pharmacological reactivation of p53 as a strategy to treat cancer, Journal of Internal Medicine, 277, 248, 10.1111/joim.12336 · DOI · Paper page
  28. Kandachi, 2004, China approves first gene therapy, Nat Biotech, 22, 3, 10.1038/nbt0104-3 · DOI · Paper page
  29. Fersht, 2003, Kinetic instability of p53 core domain mutants: implications for rescue by small molecules, J Biol Chem, 278, 24108, 10.1074/jbc.M302458200 · DOI · Paper page
  30. el-Deiry, 2002, The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein, Cancer Biol Ther, 1, 47, 10.4161/cbt.1.1.41 · DOI
  31. Wiman, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
  32. FitzGerald, 2000, In vitro display technologies - new tools for drug discovery, Drug Discov Today, 5, 253, 10.1016/S1359-6446(00)01501-4 · doi:10.1016/s1359-6446(00)01501-4
  33. Scott, 2005, The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies, Anal Biochem, 336, 145, 10.1016/j.ab.2004.09.048 · DOI
  34. Sloan, 1999, An alternating selection strategy for cloning phage display antibodies, J Immunol Methods, 228, 109, 10.1016/S0022-1759(99)00091-5 · DOI
  35. Ichimura, 2007, Rad9 modulates the P21WAF1 pathway by direct association with p53, BMC molecular biology, 8, 37, 10.1186/1471-2199-8-37 · DOI
  36. Murphy, 1997, Protein Structure and the Energetics of Protein Stability, Chemical Reviews, 97, 1251, 10.1021/cr960383c · DOI · Paper page
  37. Groner, 2005, Current strategies for the development of peptide-based anti-cancer therapeutics, J Pept Sci, 11, 713, 10.1002/psc.717 · DOI · Paper page
  38. Groner, 2005, Peptide aptamers: recent developments for cancer therapy, Expert Opin Biol Ther, 5, 783, 10.1517/14712598.5.6.783 · DOI
  39. Loffet, 2002, Peptides as drugs: is there a market?, J Pept Sci, 8, 1, 10.1002/psc.366 · DOI · Paper page
  40. Pasqualini, 1999, Anti-cancer activity of targeted pro-apoptotic peptides, Nat Med, 5, 1032, 10.1038/12469 · DOI · Paper page
  41. Barberi-Heyob, 2011, Stability of peptides and therapeutic success in cancer, Expert Opinion on Drug Metabolism & Toxicology, 7, 793, 10.1517/17425255.2011.574126 · DOI
  42. Nekrutenko, 2007, A framework for collaborative analysis of ENCODE data: making large-scale analyses biologist-friendly, Genome Res, 17, 960, 10.1101/gr.5578007 · DOI · Paper page
  43. Lipman, 1997, Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Research, 25, 3389, 10.1093/nar/25.17.3389 · DOI · Paper page
  44. Pietrokovski, 1995, Automated construction and graphical presentation of protein blocks from unaligned sequences, Gene, 163, GC17

Cited by

See all 70

Metadata

Authors
Tal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V.
Affiliations
  • Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel
  • Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2016-03-02
Volume
7
Issue
11
Pages
11817-11837
ISSN
1949-2553
DOI
10.18632/oncotarget.7857
Cited by
70
References
11
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.